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Experimental Procedures
Cloning, expression, and purification of PBP2a mutants. Wild-type PBP2a (residues 23-668) was cloned previously into pET24d(+) from the mecA sequence of Staphylococcus aureus ATCC 700699 (1) . Mutants of mecA were cloned by PCR using the following mutagenic primers:
The triple mutant (N146K/E150K and H351N) was the final product of successive PCR mutagenesis. The presence of the desired mutations was confirmed by DNA sequencing. Wild-type and mutant proteins were expressed and purified as previously described 1 with some variations. PBP2a containing fractions from anion-exchange chromatography were combined and purified on a cationexchange column (High S support resin, Bio-Rad) using a 0.2 -1 M NaCl linear gradient in 25 mM HEPES (pH 7). Fractions containing PBP2a were pooled and further purified on Sephacryl S-200 size-exclusion resin in 25 mM HEPES (pH 7), 1 M NaCl. Pure PBP2a was quantified by the BCA assay (Pierce).
Determination of Kinetic Parameters.
β-Lactam antibiotics acylate PBP2a at the active-site serine resulting in an acyl-enzyme species, as shown in Scheme S1.
Scheme S1
where E is wild-type or mutant PBP2a, EI is the non-covalent pre-acylation complex, and E-I is the covalent acyl-enzyme species.
The second-order rate constant (k 2 /K s ) for acylation of PBP2a by nitrocefin was determined as previously described. 1, 2 For ceftaroline acylation of wild-type and mutant PBP2a the k 2 /K s value was determined by a competition assay using nitrocefin as a reporter. 2, 3 Nitrocefin (120 µM) and enzyme (2.5 µM) concentrations were kept constant and the formation of the acyl-enzyme species S3 (E-I) was monitored at 500 nm (Δε 500 = 15900 M -1 cm -1 ) over time at 37 °C in the absence and presence of varying amounts of ceftaroline (0-12 µM). No measurable acylation by nitrocefin was observed at concentrations above 10 µM ceftaroline for wild-type PBP2a. The time course of A 500 was fit to equation S1,
where A is absorbance at 500 nm, A 0 is initial absorbance at 500 nm, Δε n is the change in molar absorbance of nitrocefin upon formation of the acyl-enzyme species (15,900 M -1 cm -1 ), E 0 is the concentration of PBP2a (2.5 µM), k n * is the apparent first-order rate constant for acylation by nitrocefin, k i * is the apparent first-order rate constant for acylation by ceftaroline, and N 0 is the concentration of nitrocefin used (60 µM). The second-order rate constant k 2 /K s was determined by linear regression of k i * vs concentration of ceftaroline ( Figure S1 and Table 1 in the manuscript).
Determination of Allosteric Site Binding Affinity by Fluorescent Quenching.
In order to investigate the binding of β-lactam antibiotics to the allosteric site of PBP2a, the transpeptidase active site of wild-type and mutant PBP2a was irreversibly acylated by incubation with an excess amount of oxacillin for 45 minutes at room temperature. Unbound oxacillin was removed with a protein desalting column (Pierce) and the acylated protein was used in subsequent experiments. Binding of ceftaroline to the allosteric site was determined by monitoring the intrinsic fluorescence of tryptophan and tyrosine residues of wild-type and mutant PBP2a. Using a Cary Eclipse fluorometer, 500 nM PBP2a was incubated at room temperature in buffer containing 25 mM HEPES pH 7, 1 M NaCl for 10 minutes. Upon excitation at 280 nm, emission scans of protein alone were taken, one scan per minute for three minutes. Ceftaroline or nitrocefin was titrated into the reaction 1 µL at a time and at each concentration three emission scans were taken (one per minute). The decrease in fluorescent emission at 330 nm for each concentration of ceftaroline was quantified and the decrease in fluorescence due to dilution was subtracted (determined by titration of buffer). The normalized difference in fluorescence was plotted versus antibiotic concentration. All experiments were done at least in triplicate and the averaged data was fit with the one-site binding equation S2,
where B max is the maximal binding, [AB] is the concentration of ceftaroline or nitrocefin titrated, and K d is the dissociation constant.
Crystallization.
The PBP2a single mutants (E150K, N146K) and the double mutant (N146K/E150K) were crystallized by the sitting-drop vapor diffusion method at 4 ºC using Innovaplate™ SD-2 microplates as previously described. 2 The protein solution (1 µL from each mutant concentrated up to 15-20 mg/ml) was mixed with 0.5 µL of precipitant solution consisting of 20% (v/v) PEG 550 MME, 880 mM NaCl and 16 mM CdCl 2 in 100 mM Hepes pH 7.0. The drop (approximately 1.5 µL of protein and precipitant solutions) was equilibrated against 50 µL of mother liquor.
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X-ray data collection and processing.
Prior to flash-cooling at 100K, crystals were soaked in a 70:30 (v/v) mixture of paratone/paraffin oil for cryo-protection. Diffraction data sets were collected using synchrotron radiation (beamlines ID29, ID23-1) at the ESRF facility (France), (beamline XALOC) ALBA (Spain). An in-house equipment (MicroStart rotating anode generator and a MAR345 detector) was also used to collect data sets and to test crystals. All diffraction data sets were processed using iMOSFLM 4 or XDS 5 and scaled with SCALA from the CCP4 package 6 . Data collection statistics are shown in Table 2 in the manuscript.
Structure determination and refinement.
Structures were solved by molecular replacement using the PHASER program 7 with the PBP2a structure from S. aureus (PDB code 1VQQ) as template. The models were subjected to several refinement cycles with the PHENIX 8 and BUSTER 9 programs. Water molecules were added with both programs. The stereochemistry of the models was verified with the MolProbity program 10 . Refinement statistics are given in Table 2 in the manuscript. Table S1 . New salt-bridge interactions (*) observed in the clinical PBP2a mutants. Residues are colored according to their structural regions (Lobe-1 in blue, Lobe-2 in black, Lobe-3 in red). Apo PBP2a (gray ribbons) and the E150K mutant (green ribbons) showed a similar polar interactions pattern at the allosteric site. The ceftaroline (CFT) bound at the allosteric site as observed in PDB code 3ZFZ is superimposed and depicted in black sticks. Residues involved in polar interactions are shown as grey and green sticks for apo PBP2a and the E150 single mutant respectively. In the E150K mutant the N146 is not participating in the interaction N146⋯K148⋯D295 observed in apo PBP2a, nonetheless the other two residues have the same conformation and interact in a salt bridge between them (K148⋯D295).
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N146K/E150K Mutant
Lys146···Asp295 Lys148···Asp295 Lys150···Glu239 Asp275···Lys273 Glu294···Lys319 Glu294··· Lys316 Glu268··· Lys285 Glu263··· Lys280 Lys219···Asp367 # Glu378··· Lys382 # Asp209··· Lys176 # Asp226··· Lys230
